News coverage about Clearside Biomedical (NASDAQ:CLSD) has been trending somewhat positive on Monday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Clearside Biomedical earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.9347969661747 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of research firms have recently weighed in on CLSD. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. Cowen reiterated a “buy” rating on shares of Clearside Biomedical in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Clearside Biomedical has an average rating of “Buy” and an average price target of $18.33.
Clearside Biomedical (NASDAQ CLSD) traded up $0.28 during trading hours on Monday, hitting $7.50. 127,600 shares of the stock were exchanged, compared to its average volume of 97,000. The firm has a market capitalization of $174.36 and a price-to-earnings ratio of -3.91. Clearside Biomedical has a 1 year low of $5.44 and a 1 year high of $10.46. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57.
Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.17). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.01 million. Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. equities research analysts forecast that Clearside Biomedical will post -2.37 EPS for the current fiscal year.
In related news, Director Clay Thorp sold 35,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $7.00, for a total transaction of $245,000.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Daniel H. White sold 8,000 shares of the stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $7.82, for a total transaction of $62,560.00. Following the sale, the insider now directly owns 477,935 shares in the company, valued at $3,737,451.70. The disclosure for this sale can be found here. Insiders sold 78,000 shares of company stock worth $539,060 in the last quarter. Company insiders own 20.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2018/01/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-clearside-biomedical-clsd-share-price.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.